Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00810485 · ClinicalTrials.gov registry record · Phase 2
ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
A Phase 2 study of Gastroesophageal Reflux, sponsored by Addex Pharma S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 298
- Enrollment target
- 20
- Study locations
NCT00810485: Completed Phase 2 study of Gastroesophageal Reflux, sponsored by Addex Pharma S.A..
NCT00810485 is a Phase 2 study of Gastroesophageal Reflux that has completed, run by Addex Pharma S.A.. The registered enrollment target is 298 participants, below the 2,877-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00810485, a Phase 2 study of Gastroesophageal Reflux, has completed, sponsored by Addex Pharma S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 298 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of ADX10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors
Conditions Studied
Interventions
- DRUG ADX10059
- DRUG ADX10059 Matching Placebo
Study Locations (20)
North Carolina
- - Harrisburg
- - High Point
- - Huntersville
- - Raleigh
- - Winston-Salem
Arizona
- - Little Rock
- - Tucson
California
- - Anaheim
- - San Diego
Florida
- - Jacksonville
- - Port Orange
Kansas
- 54 - Kansas City
- 62 - Kansas City
Colorado
- - Colorado Springs
Illinois
- - Moline
Mississippi
- - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2008-12 |
| Phase | Phase 2 |
What the finished NCT00810485 record still lists
NCT00810485 is an interventional study that assigns participants to a tested intervention. The registered 298 participants enrollment target is mid-sized for trials with a published cap, below the 2,877-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 2 interventions - of which ADX10059 is the first listed.
NCT00810485 names 20 study sites across 12 states, led by North Carolina, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00810485 about?
NCT00810485 is a clinical study titled "ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)". The purpose of this study is to evaluate the effect of ADX10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors
What is the current status of trial NCT00810485?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 298 participants. The study started on 2008-12.
What conditions does trial NCT00810485 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux.
What interventions are being tested in trial NCT00810485?
The interventions under investigation include: ADX10059 (DRUG), ADX10059 Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT00810485?
This trial is sponsored by Addex Pharma S.A., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00810485 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00810485's enrollment target sits among peer trials
298 7th of 33 higher than 27 of 33 other Gastroesophageal Reflux trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroesophageal Reflux trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
RECRUITING · Phase 2
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia
RECRUITING · NA
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
-
Barrett's Esophagus Related Neoplasia (BERN) Project
RECRUITING
-
External UES Band (Shaker Pressure Band) and GERD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
- NCT06754215 · 298 participants · NA
Smoking Cessation Intervention Development for Homeless Youth
- NCT06780111 · 298 participants · Phase 1
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- NCT07209358 · 298 participants · NA
EDX110 Randomized Control Trial for Treatment of DFUs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia